Testing a New Cancer Treatment Targeting XIAP
Author Information
Author(s): Cummings J, Ward T H, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C
Primary Institution: Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust
Hypothesis
Can pharmacodynamic assays effectively evaluate the clinical efficacy of the antisense compound AEG 35156 targeting XIAP?
Conclusion
The study successfully validated three pharmacodynamic assays for use in a phase I trial of AEG 35156, which targets the XIAP protein associated with cancer resistance.
Supporting Evidence
- XIAP is often overexpressed in chemoresistant tumors, making it a target for new cancer therapies.
- The validated assays showed high precision and specificity for measuring XIAP levels.
- The study emphasizes the importance of pharmacodynamic assays in evaluating new cancer treatments.
Takeaway
Researchers are testing a new treatment that targets a protein called XIAP, which helps cancer cells survive. They created tests to see if the treatment works.
Methodology
The study validated three pharmacodynamic assays: quantitative RT-PCR, Western blotting, and M30-Apoptosense™ Elisa, using cancer cell lines as quality controls.
Limitations
The assays are semiquantitative and may not fully capture the biological responses expected from the treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website